AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs
By Cygnus | 02 Jul 2026
Summary
AstraZeneca has signed a collaboration and licensing agreement worth up to $1.77 billion with China’s CSPC Pharmaceutical Group to develop experimental treatments for chronic kidney diseases using small interfering RNA (siRNA) technology. The deal expands AstraZeneca’s growing pipeline of Chinese-licensed medicines as cross-border pharmaceutical partnerships face increased scrutiny in the United States.
LONDON, July 2, 2026 — AstraZeneca has agreed to a licensing and research collaboration worth up to $1.77 billion with China’s CSPC Pharmaceutical Group to discover and develop experimental small interfering RNA (siRNA) therapies for chronic kidney diseases.
Under the agreement announced on Thursday, AstraZeneca will pay CSPC $30 million upfront. In return, the Anglo-Swedish drugmaker will receive an exclusive option to license worldwide rights to develop, manufacture and commercialize one preclinical siRNA candidate, as well as an option for exclusive rights outside China to another candidate.
The agreement is the latest example of AstraZeneca expanding its pipeline through partnerships with Chinese biotechnology companies.
Deal includes milestone payments
Beyond the initial payment, CSPC will be eligible to receive up to $540 million in development and regulatory milestone payments and as much as $1.2 billion tied to commercial sales milestones.
The Chinese company will also receive tiered royalties on future net sales if the medicines reach the market.
The collaboration will be carried out through CSPC subsidiary Jushi Biotech.
Partnership focuses on siRNA technology
The companies will work on therapies based on small interfering RNA (siRNA), a technology designed to silence disease-causing genes.
According to AstraZeneca, the research will use CSPC’s AI-powered dual-engine drug discovery platform to identify and develop new siRNA candidates for chronic kidney diseases.
The therapies remain in the preclinical stage, meaning they have not yet entered human clinical trials.
AstraZeneca continues China licensing strategy
The agreement adds to AstraZeneca’s growing list of licensing deals with Chinese biotechnology companies.
Last year, AstraZeneca signed a $2.5 billion agreement with CSPC to develop experimental treatments for hypertension and another up to $1.92 billion licensing deal involving an experimental obesity treatment.
Large pharmaceutical companies have increasingly turned to Chinese biotech firms to strengthen their drug pipelines, particularly in early-stage research.
Cross-border deals draw U.S. attention
The agreement comes as pharmaceutical collaborations with Chinese companies receive greater attention in Washington.
Earlier this week, the U.S. House Select Committee on the Chinese Communist Party requested information from several major pharmaceutical companies, including AstraZeneca, regarding licensing agreements and clinical research partnerships involving Chinese firms.
The committee said it is examining whether such collaborations could create national security or supply chain concerns.
Despite the increased scrutiny, pharmaceutical companies continue to pursue partnerships with Chinese biotechnology firms as they seek access to innovative drug candidates and research platforms.
Why this matters
- Expands AstraZeneca’s pipeline: The agreement strengthens AstraZeneca’s portfolio of experimental medicines targeting chronic kidney disease, an area with significant unmet medical need.
- Growing role of Chinese biotech: Chinese biotechnology companies continue to attract global pharmaceutical partners through early-stage drug discovery and licensing opportunities.
- AI-supported drug discovery: The collaboration will use CSPC’s AI-powered drug discovery platform to help identify potential siRNA therapies for kidney diseases.
- Political scrutiny increases: The deal comes as U.S. lawmakers examine pharmaceutical partnerships involving Chinese companies amid broader concerns over supply chains and research collaboration.
FAQs
Q1: What is the AstraZeneca-CSPC agreement worth?
The collaboration is worth up to $1.77 billion, including a $30 million upfront payment, development milestones, commercial milestone payments and royalties.
Q2: What type of medicines will the companies develop?
The partnership focuses on small interfering RNA (siRNA) therapies for chronic kidney diseases.
Q3: What rights will AstraZeneca receive?
AstraZeneca will receive an exclusive option for worldwide rights to one preclinical siRNA candidate and an option for exclusive rights outside China to a second candidate.
Q4: What role does AI play in the collaboration?
CSPC will use its AI-powered dual-engine drug discovery platform to support the discovery of new siRNA therapies.
Q5: Why is the deal attracting attention?
The agreement comes as U.S. lawmakers review pharmaceutical partnerships with Chinese biotechnology companies over potential national security and supply chain concerns.